What is a clinical trial? Is participating in a clinical trial right for you? Learn more
Urologic Neoplasms Clinical Trial in Barcelona
Have you or your loved ones been diagnosed with urologic neoplasms?
You may be eligible to participate in a urologic neoplasms clinical trial.
Have you or your loved ones been diagnosed with urologic neoplasms? You may be eligible to participate in a urologic neoplasms clinical trial.
Completed
Male & Female
18 Years +
The purpose of this trial is to assess the anti-tumour activity and safety of afatinib monotherapy in patients with urothelial tract carcinoma carrying ERBB2 or ERBB3 (Erythroblastic leukaemia viral oncogene homolog of the human epidermal growth factor family of receptors) mutations or ERBB2 amplifications (Cohort A), and EGFR (Epidermal Growth Factor Receptor) amplification positive tumours (Cohort B), progressing despite previous platinum based chemotherapy, and thereby to improve their prognosis. The antitumour activity of afatinib monotherapy in these patients will be assessed by progression free survival rate at 6 months (PFS6). This will be the primary endpoint of the trial. A key secondary endpoint will also be defined, the objective response rate (ORR).